Skip to main content

Table 2 Summary of patient demographic and disease characteristics as well as treatment outcomes in 187 CML patients treated with imatinib

From: Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia

Characteristics Variables No of pts (%)
Gender Female 79 (42)
Male 109 (58)
Age (Years, median, range) 49.0 (11–87)
Follow-up duration (Months, median, range) 41.7 (0–98.1)
Cytogenetics at diagnosis t(9;22) only 153 (81)
Additional abnormalities* 27 (15)
Unknown 7 (4)
Sokal risk group at diagnosis Low 59 (32)
Intermediate 69 (37)
High 42 (22)
Unknown 17 (9)
Disease stage at imatinib therapy CP 169 (90)
AP 11 (6)
BC 7 (4)
Previous treatment (any) De novo 145 (77.5)
Previously treated 42 (22.5)
Previous treatment prior to imatinib Interferon-alpha 30 (16.0)
Duration of imatinib therapy Median in months (range) 36.9 (0–98.1)
  1. AP accelerated phase, BC blastic crisis, CP chronic phase
  2. * Additional cytogenetic abnormalities: t(9; 22; 11) (n = 1); t(7; 9; 22) (n = 1); t(9; 22; 17) (n = 1); t(9; 22; 19) (n = 1); t(4; 22) with t(17; 20) (n = 1); inv(3) (n = 2); der(9) (n = 1); der(9), del(9) (n = 1); del(22q) (n = 1); +der(22) (n = 3); −Y(n = 1); +8(n = 1); −12 (n = 1); 92, idemx2(n = 3); 69, XXX with 92, XXXX and 138, XXXXXX (n = 1), t(8;9;22) (n = 1); dup(1) (n = 1)